Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen Looks for a New Leader; Tripos SVP Departs; and others

NEW YORK, Nov. 27-Tripos senior vice president and chief commercial officer Douglas Danne has left the firm, the company said on Nov. 25.

 

Danne joined the company in December 2000 as senior vice president of sales.

 

Tripos management is currently searching for a replacement, and will fill in for Danne in the meantime.

 

The company said that Danne left to "fulfill other interests." He was not available for comment, and Tripos did not provide further details.

 


 

Millipore said on Nov. 25 that Kevin Sanborn would replace William Emhiser as president of the company's Life Sciences division.

 

Sanborn was previously VP of strategic planning and business development.

 

The company's life sciences division develops and markets tools and services in genomics, proteomics and drug discovery. It is based in Danvers, Mass.

 

According to Millipore, Emhiser resigned.

 


 

MetaMorphix said on Nov. 25 that investment banker Fergus Reid has joined the company's board of directors.

 

Reid chairs the JP Morgan/Chase Mutual Fund Group, is chair and CEO of the Lumelite Corporation and an independent trustee of Morgan Stanley Mutual Funds.

 

His expertise in investment banking will be useful to MetaMorphix in planning an IPO, CEO and chair Edwin Quattlebaum said in a statement.

 

MetaMorphix uses genomics, growth factor research, and immunopharmaceuticals to improve livestock health. The company is based in Savage, Md.

 


 

Plant genomics researcher William Crosby has been named director of bioinformatics at the University of Saskatchewan in Saskatoon.

 

He was previously program leader of the plant genomics program at the plant biotechnology institute at the National Research Council of Canada, also located at the University of Saskatchewan.

 


 

Deltagen is looking for a new chief executive officer, the company said on Nov. 22.

 

The company is rearranging its top management in an "increased focus on operational and financial management during a challenging market environment," according to a statement.

 

The board has elected board member Constantine Anagnostopoulos as chair. Anagnostopoulos, who joined the board of Deltagen in 2001, was previously director of research at Monsanto. Anagnostopoulos will also be the first chief of a new Office of the Chairman, which will also include current company CEO William Matthews and chief financial officer Richard Hawkins.

 

In October, Deltagen laid off 130 staff-about 30 percent of staff-and announced a plan to shutter its San Diego, Calif. site in an effort to reduce spending.

 


 

 Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

 

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.